Vaccine News and Research

Latest Vaccine News and Research

Residents of many countries have a positive attitude towards Russian Sputnik V vaccine against coronavirus

The Russian Direct Investment Fund, announces the results of a survey of more than 12,000 respondents in 11 countries on their attitude towards vaccination against coronavirus and their vaccine preferences.

20 Nov 2020

Multi-institution team receives prestigious award for breakthrough research on SARS-CoV-2

The Association for Computing Machinery (ACM) awarded its first ACM Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research to a multi-institution research team that included the U.S. Department of Energy's (DOE) Argonne National Laboratory.

20 Nov 2020

Scientists develop a new vaccine approach for HIV

Unlike so many other deadly viruses, HIV still lacks a vaccine. The virus--which continues to infect millions around the world--has proven especially tricky to prevent with conventional antibodies, in part because it evolves so rapidly in the body.

20 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

NIH-funded study to test emergency treatment for devastating stroke in Memphis

The University of Tennessee Health Science Center's Stroke Team is joining researchers from more than 100 hospitals worldwide to conduct a National Institutes of Health (NIH)-funded research study called FASTEST that will test the safety and efficacy of a medication called recombinant factor Vlla to prevent hemorrhage expansion in patients with strokes caused by bleeding in the brain - intracerebral hemorrhage strokes.

19 Nov 2020

Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2

The researchers show that the mice immunized with homotypic or mosaic nanoparticles produced broad binding and neutralizing responses, in contrast to plasma antibodies elicited in humans by SARS-CoV-2 infection. The RBD nanoparticles induced cross-reactive IgG responses in the immunized mice.

19 Nov 2020

Texas Biomed awarded $1 million to evaluate MAb therapeutics for COVID-19

Texas Biomedical Research Institute in San Antonio, Texas, was awarded $1 million from the Bill & Melinda Gates Foundation to test the efficacy of human monoclonal antibodies (MAbs) for the treatment of SARS-CoV-2 infection.

19 Nov 2020

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Researchers from the United States and The Netherlands have conducted a pre-clinical study supporting the initiation of a Phase 3 trial to test a two-dose regimen of the Janssen Ad26.COV2.S vaccine candidate among adult and elderly individuals.

19 Nov 2020

SARS-CoV-2 immunity can last over six months, study finds

US-based scientists have released a study on preprint server bioRxiv*, titled “Immunological memory to SARS-CoV-2 assessed for greater than six months after infection,” contributing to the enormous research effort currently underway in this area.

19 Nov 2020

Take it from an expert: Fauci’s hierarchy of safety during COVID

As a health journalist, a physician and a former foreign correspondent who lived through SARS in Beijing, I often get questions from friends, colleagues and people I don't even know about how to live during the pandemic.

19 Nov 2020

Study describes the early evolution of oral poliovirus vaccine

While the world reels from the spread of SARS-CoV2, the new coronavirus behind COVID-19, a much older and previously feared scourge--poliovirus--is close to being completely eradicated.

19 Nov 2020

People with learning disabilities are more likely to die from coronavirus

A newly-published Public Health England report which shows people with learning disabilities are 6.3 times more likely to die from coronavirus than the rest of the population shows urgent action is required.

19 Nov 2020

Predictive model identifies neighborhoods that have greatest risk of COVID-19 infection

To help slow the spread of COVID-19 and save lives, UCLA public health and urban planning experts have developed a predictive model that pinpoints which populations in which neighborhoods of Los Angeles County are most at risk of becoming infected.

19 Nov 2020

Domestic cats can be asymptomatic carriers of SARS-CoV-2, show studies

Two recently published studies from Kansas State University researchers and collaborators have led to two important findings related to the COVID-19 pandemic: Domestic cats can be asymptomatic carriers of SARS-CoV-2, but pigs are unlikely to be significant carriers of the virus. SARS-CoV-2 is the coronavirus responsible for COVID-19.

19 Nov 2020

TB researchers uncover crucial clue that explains antibiotic resistance in bacteria

For a slow-growing microbe that multiplies infrequently, Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB) has long puzzled researchers as to how it develops resistance to antibiotics so quickly, in a matter of weeks to months.

18 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

UIC conducts three clinical trials to study blood clot prevention in COVID-19 patients

The University of Illinois Chicago will conduct three clinical trials for studying blood clot prevention in patients with COVID-19.

18 Nov 2020

Optimizing SARS-COV-2 inactivation for COVID-19 research at lower biosafety levels

Researchers at Montana State University have validated and compared two methods for inactivating the causative agent of coronavirus disease 2019 (COVID-19) that would enable the virus to be studied at a lower biosafety level (BSL) than the one currently required.

18 Nov 2020

"Escape mutations" could help SARS-CoV-2 evade immune attack

Researchers in the United States have identified mutations within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that can reduce antibody binding to the virus, potentially mediating its escape from immune attack.

18 Nov 2020